GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » NonCurrent Deferred Liabilities

Microba Life Sciences (ASX:MAP) NonCurrent Deferred Liabilities : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Microba Life Sciences's non-current deferred liabilities for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Microba Life Sciences NonCurrent Deferred Liabilities Historical Data

The historical data trend for Microba Life Sciences's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences NonCurrent Deferred Liabilities Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23
NonCurrent Deferred Liabilities
- -

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities - - - - -

Microba Life Sciences NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Microba Life Sciences's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Microba Life Sciences (ASX:MAP) Business Description

Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome which includes delivering gut microbiome testing services globally to consumers, clinicians, and researchers. The company's segment includes Testing Services, and Research and Development.

Microba Life Sciences (ASX:MAP) Headlines

No Headlines